This document aims to assist oncologists in making clinical decisions encountered while managing their patients with hepatocellular carcinoma (HCC), specific to Indian practice, based on consensus among experts. Most patients are staged by Barcelona Clinic Liver Cancer (BCLC) staging system which comprises patient performance status, Child-Pugh status, number and size of nodules, portal vein invasion and metastasis. Patients should receive multidisciplinary care. Surgical resection and transplant forms the mainstay of curative treatment. Ablative techniques are used for small tumours (<3 cm) in patients who are not candidates for surgical resection (Child B and C). Patients with advanced (HCC should be assessed on an individual basis to determine whether targeted therapy, interventional radiology procedures or best supportive care should be provided. In advanced HCC, immunotherapy, newer targeted therapies and modern radiation therapy have shown promising results. Patients should be offered regular surveillance after completion of curative resection or treatment of advanced disease.

中文翻译：

---

印度医学研究理事会关于肝细胞癌的共识文件

该文件旨在根据专家们的共识，协助肿瘤学家在管理其肝细胞癌（HCC）患者时遇到的临床决策，这是印度实践所特有的。大多数患者由巴塞罗那临床肝癌（BCLC）分期系统分期，该系统包括患者的表现状态，Child-Pugh状态，结节的数量和大小，门静脉的侵袭和转移。患者应接受多学科护理。手术切除和移植是治疗的主要手段。对于不适合手术切除的患者（儿童B和C），消融技术可用于较小的肿瘤（<3 cm）。晚期（HCC）患者应进行个体评估，以确定是否有针对性的治疗，应提供介入放射学程序或最佳支持治疗。在晚期肝癌中，免疫疗法，新型靶向疗法和现代放射疗法已显示出令人鼓舞的结果。完成根治性切除或晚期疾病的治疗后，应定期给予患者监测。